

Date of Publication: 30/6/2023

	Full Name <i>(Άρθρο 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Άρθρο 3)</i>	Country of Principal Practice <i>(Παράρτημα 1)</i>	Principal Practice Address <i>(Άρθρο 3)</i>	Donations and Grants to HCOs(άρθρο 3.01.1.α)	Contribution to costs of Events <i>(Άρθρα 3.01.1.β & 3.01.2.α)</i>			Fee for service and consultancy <i>(Άρθρα. 3.01.1.γ & 3.01.2.β)</i>		Total Optional	
						Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
ATOMIKA	HCPs				Aggregate amount attributable to transfers of value to such Recipients			150,00	1.128,53	0,00	0,00	1.278,53 €
	Number of Recipients in aggregate disclosure						1	2	0	0	2,00 €	
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						100%	100%	0%	0%	1,00 €	
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
HCOs	AIDS Solidarity Movement	Nicosia	Cyprus	Vasiliou Voulgaroktonou 44-46	0,00	3.000,00	0,00	0,00	0,00	0,00	3.000,00	
	Aggregate amount attributable to transfers of value to such Recipients											
	Number of Recipients in aggregate disclosure											
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed				0%	0%	0%	0%	0%	0%	0%	- €	
R&D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined										0,00	